Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study

被引:162
作者
Langan, Sinead M. [1 ]
Smeeth, Liam [1 ]
Margolis, David J. [2 ,3 ]
Thomas, Sara L. [1 ]
机构
[1] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England
[2] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
关键词
RISK-FACTORS; COMPLICATION RATES; INFECTION; CHILDREN;
D O I
10.1371/journal.pmed.1001420
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Herpes zoster is common and has serious consequences, notably post-herpetic neuralgia (PHN). Vaccine efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effectiveness has not been studied in unselected general populations unrestricted by region, full health insurance coverage, or immune status. Our objective was to assess zoster vaccine effectiveness (VE) against incident zoster and PHN in a general population-based setting. Methods and Findings: A cohort study of 766,330 fully eligible individuals aged >= 65 years was undertaken in a 5% random sample of Medicare who received and did not receive zoster vaccination between 1st January 2007 and 31st December 2009. Incidence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated individuals. Analyses were adjusted for age, gender, race, low income, immunosuppression, and important comorbidities associated with zoster, and then stratified by immunosuppression status. Adjusted hazard ratios were estimated using time-updated Cox proportional hazards models. Vaccine uptake was low (3.9%) particularly among black people (0.3%) and those with evidence of low income (0.6%). 13,112 US Medicare beneficiaries developed incident zoster; the overall zoster incidence rate was 10.0 (9.8-10.2) per 1,000 person-years in the unvaccinated group and 5.4 (95% CI 4.6-6.4) per 1,000 person-years in vaccinees, giving an adjusted VE against incident zoster of 0.48 (95% CI 0.39-0.56). In immunosuppressed individuals, VE against zoster was 0.37 (95% CI 0.06-0.58). VE against PHN was 0.59 (95% CI 0.21-0.79). Conclusions: Vaccine uptake was low with variation in specific patient groups. In a general population cohort of older individuals, zoster vaccination was associated with reduction in incident zoster, including among those with immunosuppression. Importantly, this study demonstrates that zoster vaccination is associated with a reduction in PHN.
引用
收藏
页数:11
相关论文
共 17 条
[1]  
Center for Medicare and Medicaid Services, 2009, CTR MED MED SERV 200
[2]   THE INCIDENCE OF HERPES-ZOSTER [J].
DONAHUE, JG ;
CHOO, PW ;
MANSON, JE ;
PLATT, R .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (15) :1605-1609
[3]   The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era [J].
Gebo, KA ;
Kalyani, R ;
Moore, RD ;
Polydefkis, MJ .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (02) :169-174
[4]   A PHASE I-II STUDY OF LIVE ATTENUATED VARICELLA-ZOSTER VIRUS VACCINE TO BOOST IMMUNITY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN WITH PREVIOUS VARICELLA [J].
Gershon, Anne A. ;
Levin, Myron J. ;
Weinberg, Adriana ;
Song, Lin-Yee ;
LaRussa, Philip S. ;
Steinberg, Sharon P. ;
Bartlett, Patterson .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (07) :653-655
[5]   Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era [J].
Gourishankar, S ;
McDermid, JC ;
Jhangri, GS ;
Preiksaitis, JK .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (01) :108-115
[6]  
Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
[7]   The impact of herpes zoster and post-herpetic neuralgia on quality-of-life [J].
Johnson, Robert W. ;
Bouhassira, Didier ;
Kassianos, George ;
Leplege, Alain ;
Schmader, Kenneth E. ;
Weinke, Thomas .
BMC MEDICINE, 2010, 8
[8]   Herpes Zoster and Postherpetic Neuralgia Surveillance Using Structured Electronic Data [J].
Klompas, Michael ;
Kulldorff, Martin ;
Vilk, Yury ;
Bialek, Stephanie R. ;
Harpaz, Rafael .
MAYO CLINIC PROCEEDINGS, 2011, 86 (12) :1146-1153
[9]   A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults [J].
Oxman, MN ;
Levin, MJ ;
Johnson, GR ;
Schmader, KE ;
Straus, SE ;
Gelb, LD ;
Arbeit, RD ;
Simberkoff, MS ;
Gershon, AA ;
Davis, LE ;
Weinberg, A ;
Boardman, KD ;
Williams, HM ;
Zhang, JHY ;
Peduzzi, PN ;
Beisel, CE ;
Morrison, VA ;
Guatelli, JC ;
Brooks, PA ;
Kauffman, CA ;
Pachucki, CT ;
Neuzil, KM ;
Betts, RF ;
Wright, PF ;
Griffin, MR ;
Brunell, P ;
Soto, NE ;
Marques, AR ;
Keay, SK ;
Goodman, RP ;
Cotton, DJ ;
Gnann, JW ;
Loutit, J ;
Holodniy, M ;
Keitel, WA ;
Crawford, GE ;
Yeh, SS ;
Lobo, Z ;
Toney, JF ;
Greenberg, RN ;
Keller, PM ;
Harbecke, R ;
Hayward, AR ;
Irwin, MR ;
Kyriakides, TC ;
Chan, CY ;
Chan, ISF ;
Wang, WWB ;
Annunziato, PW ;
Silber, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2271-2284
[10]   Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years [J].
Schmader, Kenneth E. ;
Levin, Myron J. ;
Gnann, John W., Jr. ;
McNeil, Shelly A. ;
Vesikari, Timo ;
Betts, Robert F. ;
Keay, Susan ;
Stek, Jon E. ;
Bundick, Nickoya D. ;
Su, Shu-Chih ;
Zhao, Yanli ;
Li, Xiaoming ;
Chan, Ivan S. F. ;
Annunziato, Paula W. ;
Parrino, Janie .
CLINICAL INFECTIOUS DISEASES, 2012, 54 (07) :922-928